The Netherlands-based company, founded in 2011 as a spin-out of Philips Healthcare, develops in vivo chemistry to enhance the efficacy of cancer treatments through the actuation of tagged antibodies. Tagworks' facilities are located at the Radboud University Medical Center in Nijmegen, where they use their antibody-based imaging and therapy technology to improve established approaches like radioimmuno-imaging and therapy and antibody-drug conjugates. The company's unique approach towards antibody-based imaging and therapy has the potential to revolutionize cancer treatment.